A Phase I trial tested allogeneic iPSC‑derived invariant natural killer T (iNKT) cells in patients with recurrent head and neck cancer, reporting initial clinical findings from the first‑in‑human program. The study evaluates safety, feasibility and early anti‑tumor activity of an off‑the‑shelf, stem‑cell‑derived immunotherapy intended to deliver tumor‑directed cytotoxicity without the manufacturing delays of autologous approaches. iNKT cells are a rare immune subset with rapid effector function; deriving them from iPSCs aims to create standardized, scalable cell products. Sponsors noted that additional cohorts and longer follow‑up are required to define durability and efficacy.